AB0619 Rationale and Design of the 52-Week, Randomized, Phase 3, Head-to-Head MANDARA Study to Evaluate the Efficacy and Safety of Benralizumab, a Humanized, Anti-interleukin–5 Receptor Α Monoclonal Antibody in Refractory or Relapsing Eosinophilic Granulomatosis with Polyangiitis
Annals of the Rheumatic Diseases（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined